Who's Your Mother?

Though she is a drug, she ain't like all the rest.

She was born to heal, unlike the others born to steal.

Big Pharma is a System. But this System is about to sprout forth something unfamiliar.

The world knows nothing but Big Pharma's concoctions. The world is drunk with her wine.

Her wine of course is her drugs. Every approved drug embodies her teachings and her doctrines.

But these doctrines go against the doctrines of leronlimab.

After all, what other drug modulates CCR5? I don't know of another monoclonal antibody that blocks CCR5 other than leronlimab. There are a few small molecule drugs like maraviroc, centriviroc and vicriviroc that do it, but I believe that only maraviroc is approved and despite that, it remains a poor blockade of CCR5.

So, because we stand alone as a large molecule CCR5 blockade, we are unfamiliar to Big Pharma. In general, intracellular communication is a foreign language to them. Therefore, we are like a black sheep. They don't know what to do with us. They are unfamiliar with this Cytokine business.

Everything we can do, they cannot. And everything they do, we do not.

We are multimodal, they are unimodal.

We are multifunctional, they are singularly functional.

We are healing, they are hiding or masking.

They sicken with side effects; we have none.

They address in part, while we address in full.

They leave in dissatisfaction while we leave satisfied.

Why are we so different when we were created by one of their own? Because we are one of a kind. There is no one like us. We are unlike any other, that operates at the heart of intra-cellular communication. And because this communication controls the behavior of the entire immune system, the methods that the immune system takes to overcome any one disease is directly affected when the intra-cellular communication channels are disrupted by this molecule. The one molecule affects the manner by which the immune system goes about overcoming every single disease and it is because of this reason why leronlimab is a multimodal drug.

But how can we have been born out of the mono-clonal antibodies? Well, it is true, that we are a mono-clonal antibody and there ain't anything on Earth that fits better than leronlimab into the CCR5 receptor. Leronlimab has even greater affinity for that receptor than its own ligand, CCL5 or RANTES. Yes, leronlimab pushes RANTES out of the CCR5 receptor and takes the place of RANTES because of its higher affinity. But the inventors thought they were only constructing a drug that would only treat HIV and prevent AIDS. Well, this monoclonal antibody, though it fits precisely into only one protein in the entire human body, and the only thing that it attaches to there in is CCR5, well, the inventors had no idea that what they were inventing by choosing that one receptor protein, that instead of overcoming the treatment of just one disease namely HIV, they in fact had developed a single antibody that treats the gamut of disease processes across the Inflammation and Immune Activation spectrum.

The majority of BP drugs handle one disease and one disease only. Penicillin treats gram positive bacteria. Acetaminophen treats pain. Aspirin reduces inflammation and also thins the blood. That one has 2 modalities.

This is how BP has operated for years and years. Well, things are about to morph, and they have been fighting this change for years already, but when things got to change, they will finally come to the point where there are no other choices, and they have to bite the bullet.

I believe, when BP tried drugs in the past with multiple indications, these drugs usually were plagued with multiple side effects. So, by zeroing in on only one indication, most of the side effects could be weeded out to the point that the drug could become FDA approved. The name of the game of course was to make money, but they couldn't make money if they couldn't get their drugs approved. So that led to the preponderance of single use drugs. And this is exactly how they wanted the playing field to remain, because they need to make money. To them it does not matter how many drugs are out there. All that matters is that they make money on every single unimodal drug ever invented.

But leronlimab was created and found to treat a myriad of disease processes superbly well and free from any side effects. It was found to be very well tolerated and found to heal in the face of many disease states where no other unimodal drug would do. Despite all the odds against it, leronlimab, though only binding to a single solitary CCR5 protein, was found to be treating HIV, all kinds of Tumors, allowing patients stricken with COVID 19 and on respirators for weeks and weeks to be taken off respiratory therapy after only one day of use. It was found to reduce Steatosis and Fibrosis in patients with MASH while in all of BP, there was not even one drug that treats MASH until very recently.

Tremendous resistance came upon this drug leronlimab and upon the company developing it CytoDyn, possibly because of the unorthodox mechanism of action that blocks CCR5 and by doing so, is capable of treating the myriad of disease processes across the board of Inflammation and Immune Activation. The drug was put on hold by the FDA and a warning letter hung to prevent its use.

Over the course of 2.5 years, a man by the name of Cyrus Arman was very instrumental in his work towards getting that hold removed. Later on, towards the end of those years, another man by the name of Jacob Lalezari, MD was the CEO in charge of CytoDyn at the time when the hold was finally lifted and was probably done largely because of his cooperation with the FDA. Well, both of these men remain with CytoDyn to this day. Both of these men are staunch believers in the mechanism of action of leronlimab.

Well, even though the hold was lifted, a period of about 6 months followed that required much hand holding, as if the company forgot how to ride a bike and the training wheels needed to be placed again so it could learn how to ride and, on every ride, somebody would always run up to them and taunt them, intentionally trying to make them fall. For some reason, nobody cared that CytoDyn should succeed. It really appeared that the many out there hoped and prayed for its demise.

But a time came, when a decision became necessary as to what to do with CytoDyn. After all, they in fact owned a Wonderdrug. A drug that when combined with their own drug could make their own drug perform twice as good. It could provide them with the means by which to treat a myriad of diseases that remain currently untreatable. A drug that would open up for them hundreds of billions of dollars in revenue that currently remain untapped.

In their consideration of CytoDyn, they took into account the myriad of peer reviewed research papers that proclaim the tremendous benefits on the use of CCR5 blockade in the treatment of so many diseases. They have reviewed the results of the various CytoDyn trials in HIV, in COVID and in Oncology. And these results are forthcoming, but these CytoDyn partners have already seen what we are about to see.

So, they came to a decision to unite together to keep hope alive for the people they treat as well as for their own shareholders. In addition, they are sure to gain the monetary benefits that comes along with the ability to treat 85% of the tumors that remain untreatable today. So, despite the contempt and original rejection of their very own brother, in the end, they have come together united with their brother so that both might benefit by their symbiotic relationship.

And why do these brothers behave as such? Well, so as to please their same Mother. And who is their Mother? The FDA. All play by the same book of rules. The FDA knows of the myriad of indications that leronlimab shall treat. They know of the revenues that shall come on behalf of this drug and they have opened up the highways for this drug to pass on through. Both we and our brother have seen and heard what our Mother, the FDA wants, and both of us follow those orders.

Later, once well known in the land of which it treats, leronlimab becomes a household name, then it becomes understood, that no other drug really is necessary.